trending Market Intelligence /marketintelligence/en/news-insights/trending/GN4KHG-urnKdNK2eQpgXLQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

ImmunoPrecise to invest in Dutch protein therapeutics company

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


ImmunoPrecise to invest in Dutch protein therapeutics company

ImmunoPrecise Antibodies Ltd. signed a binding letter of intent to invest €250,000 for 35% of the capital stock in SERPINx BV to assist in the development of recombinant protease inhibitors to treat bradykinin-mediated diseases.

The company will have the right of first option to acquire the remaining outstanding and issued shares of SERPINx before any other third party or before any additional funding with any other third party.

In addition, the letter sets forth SERPINx's commitment to undertake and fund animal trials for its proprietary lead compounds at ImmunoPrecise's Victoria facilities.

SERPINx is a Dutch protein therapeutics company involved in developing novel serine protease inhibitor therapeutics for inflammatory-associated diseases, in particular angioedema.

The companies will carry out due diligence until Jan. 15, 2018, after which they will enter a shareholder agreement setting forth the terms and conditions of the investment.